Pharmacy Benefit Manager (PBM) Reform
Where Things Stand
Both S. 882 and S. 3345 are currently stalled in the Senate Committee on Finance, halting efforts to mandate flat-fee models and ban spread pricing in Medicaid. Until these measures advance, Medicare patients remain subject to pricing structures where PBMs can retain drug rebates rather than passing savings directly to consumers.
The Facts
How We Got Here
Key Statements
“GOPoversight exposed how the three largest PBMs colluded to line their own pockets. These self-benefitting tactics have done nothing but jeopardize patient care.”
This post highlights the specific allegations of collusion and patient harm that drive the push for PBM reform.
“Pharmacy benefit managers shouldn’t steer patients to affiliated pharmacies and treatments regardless of price or effectiveness.”
This quote directly addresses the 'steering' practice that S. 882 and S. 3345 aim to restrict.
Who This Affects
Conflicting
Helps
Policies
S. 882 and S. 3345 are complementary Senate bills; S. 882 focuses on Medicare rebate pass-throughs and flat fees, while S. 3345 targets Medicaid transparency and spread pricing. They are often discussed together as a package alongside House companion bills like HR 7148 to provide a comprehensive overhaul of PBM business practices.
Political Response
Analysis generated by AI. Always verify with official sources.